FDA Drug Label
VYLEESI (bremelanotide injection) for subcutaneous use - Prescribing Information
AMAG Pharmaceuticals. FDA Drug Label. 2019
Compare
PT-141 vs Retatrutide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
PT-141
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 4% · Mixed 3% · Unfavorable overall 93%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Libido
115
Mood
2
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
38
Headache
37
Injection site irritation
35
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
1
0.2–0.4 mg
2
0.4–0.6 mg
9
0.6–1 mg
3
1–2 mg
9
2–3 mg
90
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 100 days · Based on 23 repeat reporters
Retatrutide
125 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 99% · Mixed 1% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
222
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
5
0.1–0.2 mg
3
0.2–0.4 mg
6
0.4–0.6 mg
10
0.6–1 mg
5
1–2 mg
80
2–3 mg
35
3–5 mg
17
5+ mg
61
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 45 repeat reporters
Sources (11)
Published sources linked on the PT-141 and Retatrutide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Bremelanotide: New Drug for Treating Hypoactive Sexual Desire Disorder
Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019
- Wiki study page →Source
ClinicalTrials.gov
Bremelanotide (PT-141) studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
Pettigrew JA, Novick AM. Journal of midwifery & women's health. 2021
- Wiki study page →Source
PubMed
Pharmacologic therapeutic options for sexual dysfunction
Burton CS, Mishra K. Current opinion in obstetrics & gynecology. 2022
- Wiki study page →Source
PubMed
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. The New England journal of medicine. 2023
- Wiki study page →Source
PubMed
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V, Koutsopoulos G, Fragoulis C, et al. Biomolecules. 2025